Clinical evaluation of changes in biomarkers by oral intake of NMN

• 資料種別: 記事
• タイトル: Clinical evaluation of changes in biomarkers by oral intake of NMN
• 著者・編者: Yuji Morita; Hiromi Izawa; Atsuyuki Hirano
• 出版事項: 日本 : 糖化ストレス研究会
• 出版年月日等: 2022-06-30
• 出版年（W3CDTF）: 2022-06-30
• 並列タイトル等: NMN経口摂取による各種バイオマーカーの推移についての臨床的評価
• タイトル（掲載誌）: Glycative stress research
• 巻号年月日等（掲載誌）: 9(2)
• 掲載巻: 9(2)
• ISSN（掲載誌）: 2188-3610
• ISSN-L（掲載誌）: 2188-3610
• 本文の言語コード: eng; jpn
• DOI: 10.24659/gsr.9.2_33; https://doi.org/10.24659/gsr.9.2_33
• 国立国会図書館永続的識別子: info:ndljp/pid/13120768; https://dl.ndl.go.jp/pid/13120768
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• 収集根拠: オンライン資料収集制度
• 受理日（W3CDTF）: 2023-12-08T11:19:22+09:00
• 保存日（W3CDTF）: 2023-05-20
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: https://www.toukastress.jp/webj/page-2
• 掲載誌（国立国会図書館永続的識別子）: info:ndljp/pid/13120767; https://dl.ndl.go.jp/pid/13120767
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 所蔵機関: 国立国会図書館
• 請求記号: Z63-D541
• 関連情報（URI）: https://dl.ndl.go.jp/info:ndljp/pid/13120768
• 関連情報（国立国会図書館永続的識別子）: info:ndljp/pid/13120768; https://dl.ndl.go.jp/info:ndljp/pid/13120768
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館雑誌記事索引; https://ndlsearch.ndl.go.jp
• 書誌ID（NDLBibID）: 032834787; http://id.ndl.go.jp/bib/032834787
• 整理区分コード: 632

• 要約等: Purpose: The "NAD World" (proposed by Professor Shin-Ichiro Imai of the University of Washington), in which the control of aging, lifespan, and metabolism is systemically integrated through NAD (nicotinamide adenine dinucleotide), has attracted worldwide attention and is being studied from various angles, however, there are few reports of clinical studies in humans. In this study, we investigate the changes in various biomarkers in humans after oral intake of nicotinamide mononucleotide (NMN), a precursor of NAD, and evaluate its clinical significance. Methods: Based on the approval to start the study at the ethics review, 17 postmenopausal women (mean age 55.0 years) without underlying diseases who agreed to participate in the study were subjects and received oral intake of 300 mg/day of pure NMN for eight weeks. The examination items included body measurements, basal metabolic rate, blood pressure, grip strength, glycation level (AF value), blood biochemical tests, various hormones, blood SIRT1 mRNA expression and NMN, NAD and NAM levels, immunological tests (aging, T cell subset including exhausted cells), and skin VAS (visual analog scale). Results were statistically analyzed and compared at zero and eight weeks (blood biochemistry tests were performed at four weeks to confirm safety). In addition, we asked the patients to keep a diary during the course of the study to monitor their NMN intake, their bodily sensation, and side effects. Results: One of the 17 subjects dropped out at the end of four weeks due to persistent mild headache. The results showed significant changes in NAM (nicotinamide/vitamin B3) from 45.2 to 164.7 (p < 0.001), adiponectin from 13.6 to 16.2 (p = 0.004), and skin VAS score (6/7 items, p < 0.001 to = 0.001) before and after intake. Significant differences were also observed for BMI, AF levels, platelets, HbA1c, HDL-C, amylase, DHEA-s, NAD, and narrowly defined regulatory T cells (p < 0.05 above). In addition, all subjects showed a positive bodily sensation with skin, sleep, and fatigue. There were no problems with subjective symptoms or laboratory data in the 16 who completed the study. Conclusion: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers, suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control in humans.
• DOI: 10.24659/gsr.9.2_33
• オンライン閲覧公開範囲: インターネット公開
• 連携機関・データベース: 科学技術振興機構 : J-STAGE; http://www.jstage.jst.go.jp

• 要約等: Purpose: The "NAD World" (proposed by Professor Shin-Ichiro Imai of the University of Washington), in which the control of aging, lifespan, and metabolism is systemically integrated through NAD (nicotinamide adenine dinucleotide), has attracted worldwide attention and is being studied from various angles, however, there are few reports of clinical studies in humans. In this study, we investigate the changes in various biomarkers in humans after oral intake of nicotinamide mononucleotide (NMN), a precursor of NAD, and evaluate its clinical significance. Methods: Based on the approval to start the study at the ethics review, 17 postmenopausal women (mean age 55.0 years) without underlying diseases who agreed to participate in the study were subjects and received oral intake of 300 mg/day of pure NMN for eight weeks. The examination items included body measurements, basal metabolic rate, blood pressure, grip strength, glycation level (AF value), blood biochemical tests, various hormones, blood SIRT1 mRNA expression and NMN, NAD and NAM levels, immunological tests (aging, T cell subset including exhausted cells), and skin VAS (visual analog scale). Results were statistically analyzed and compared at zero and eight weeks (blood biochemistry tests were performed at four weeks to confirm safety). In addition, we asked the patients to keep a diary during the course of the study to monitor their NMN intake, their bodily sensation, and side effects. Results: One of the 17 subjects dropped out at the end of four weeks due to persistent mild headache. The results showed significant changes in NAM (nicotinamide/vitamin B3) from 45.2 to 164.7 (p < 0.001), adiponectin from 13.6 to 16.2 (p = 0.004), and skin VAS score (6/7 items, p < 0.001 to = 0.001) before and after intake. Significant differences were also observed for BMI, AF levels, platelets, HbA1c, HDL-C, amylase, DHEA-s, NAD, and narrowly defined regulatory T cells (p < 0.05 above). In addition, all subjects showed a positive bodily sensation with skin, sleep, and fatigue. There were no problems with subjective symptoms or laboratory data in the 16 who completed the study. Conclusion: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers, suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control in humans.
• DOI: 10.24659/gsr.9.2_33; https://doi.org/10.24659/gsr.9.2_33
• 関連情報（URI）: http://id.ndl.go.jp/bib/032834787; https://ndlsearch.ndl.go.jp/books/R000000004-I032834787; https://dl.ndl.go.jp/pid/13120768; http://id.ndl.go.jp/digimeta/13120768; https://search.jamas.or.jp/link/ui/2023252494
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp
• 書誌ID（NDLBibID）: 032834787; http://id.ndl.go.jp/bib/032834787; 13120768; http://id.ndl.go.jp/bib/13120768